Calcium Channel Blockers
Calcium Channel Blockers
Calcium channel blockers are medications commonly used to treat high blood pressure. The potential effect of these medications on development of chemotherapy-induced peripheral neuropathy was studied.
Effectiveness Not Established
Research Evidence Summaries
Tatsushima, Y., Egashira, N., Narishige, Y., Fukui, S., Kawashiri, T., Yamauchi, Y., & Oishi, R. (2013). Calcium channel blockers reduce oxaliplatin-induced acute neuropathy: A retrospective study of 69 male patients receiving modified FOLFOX6 therapy. Biomedicine & Pharmacotherapy, 67, 39-42.doi: 10.1016/j.biopha.2012.10.006
Determine whether treatment with calcium channel blockers prevented oxaliplatin-induced acute neuropathy
Intervention Characteristics/Basic Study Process:
Retrospective chart review was conducted to obtain data, and analysis was performed to determine differences in neuropathy symptoms between patients who were and were not on calcium channel blockers.
- N = 69
- MEAN AGE = 62 years for the control group and 70 years for the intervention group
- MALES = 100%
- KEY DISEASE CHARACTERISTICS: Colorectal cancer; no staging data provided
- OTHER KEY SAMPLE CHARACTERISTICS: 35% of patients in the calcium channel blocker group were diabetic.
- SITE: Single site
- SETTING TYPE: Not specified
- LOCATION: Japan
Phase of Care and Clinical Applications:
PHASE OF CARE: Active antitumor treatment
Two-group, retrospective, cross-sectional
- Acute neuropathy charts were reviewed for symptoms of acute neuropathy including cold hypersensitivity, perioral paresthesias, shortness of breath, difficulty swallowing, pharyngolaryngeal dysesthesia, throat and jaw tightness, and dysphonia.
- Chronic neuropathy was evaluated using change of chemotherapy schedule and addition of supplementary analgesics.
The incidence of acute neurotoxicity was lower in the calcium channel group; however, no differences existed related to chronic neuropathy.
Patients receiving calcium channel blockers may experience less acute neurotoxicity than those not receiving calcium channel blockers, but more well-designed studies are needed before any conclusions can be made.
- Measurement validity/reliability was questionable.
- Study design was retrospective.
- Study primarily focused on acute oxaliplatin-induced neurotoxicity, which is a unique side effect of oxaliplatin and distinctly different from chemotherapy-induced peripheral neuropathy, which is chronic and has a different presentation and trajectory.
- Patients were already on calcium channel blockers when they enrolled in the study.
More studies are needed before any clinical implications can be made.